Aortic Valve Replacement for Severe Aortic Stenosis Before and During the Era of Transcatheter Aortic Valve Implantation - 08/06/20
, Tomo Ando, MD, PhD b, Aubin Sandio, MPH c, Oluwole Adegbala, MD, MPH c, Mohamed Salih, MD a, Josiah Zubairu, MD a, Abdullahi Oseni, MD a, Phanicharan Sistla, MD a, Musab Alqasrawi, MD a, Alexander Egbe, MD, MPH d, Amgad Mentias, MD a, Luis Afonso, MD c, Alexandros Briasoulis, MD, PhD a, Sidakpal Panaich, MD a, Milind Y. Desai, MD eRésumé |
Recent positive results of transcatheter aortic valve replacement (TAVI) in clinical trials have sparked debate on whether TAVI should be first line for all patients with aortic stenosis. However, limited evidence exists on the clinical impact of TAVI on a national level. Using the national inpatient sample (NIS) of hospital discharges in the United States from 2001 to 2016, we evaluated the rate of AVR and associated in-hospital outcomes in pre-TAVI and TAVI era. Hierarchical mixed effect modeling was used to assess for trend and calculate risk adjusted estimates. Annual volume of AVR increased from 49,357 in 2001 to 100,050 in 2016 (103% increase). Compared with the pre-TAVI era, mean annual change in volume of AVR was higher in the TAVI era (+2.9% vs +9.4%, respectively, p <0.001). In contrast, rate of in-hospital mortality decreased from 5.4% in 2001 to 2.7% in 2016 (50% decrease). Compared with the pre-TAVI era, magnitude of mean annual change in mortality was higher in TAVI era (−4.0% vs −6.7%, respectively, p = 0.04). Unlike SAVR for which risk-adjusted rate for most outcomes seems to have plateaued, TAVI demonstrated significant improvement from 2012 to 2016 for mortality (4.6% to 1.8%), acute kidney injury (15.1% to 2.6%) and nonroutine home discharge (63.6% to 44.6%). However, no significant change in the rate of stroke (2.4% to 2.1%) and pacemaker implantation remained high (8.1% to 9.4%). Lastly, median length of stay was shorter for TAVI compared with isolated SAVR (3 vs 8 days, respectively). In conclusion, the adoption of TAVI has led to increase in volume of AVR for severe aortic stenosis in the United States with favorable short-term outcome.
Le texte complet de cet article est disponible en PDF.Plan
Vol 126
P. 73-81 - juillet 2020 Retour au numéro
Article précédent
- Additive Value of High-Density Lipoprotein Cholesterol and C-Reactive Protein Level Assessment for Prediction of 2-year Mortality After Transcatheter Aortic Valve Implantation
- Kamil Zieli?ski, ?ukasz Kali?czuk, Zbigniew Chmielak, Gary S Mintz, Maciej D?browski, Jerzy Pr?gowski, Micha? ?wierczewski, Ilona Kowalik, Marcin Demkow, Tomasz Hryniewiecki, Ilona Micha?owska, Adam Witkowski
- Effect of Transcatheter Aortic Valve Implantation on Renal Function in Patients With Chronic Kidney Disease
- Takuma Takada, Kentaro Jujo, Yutaka Konami, Hisao Otsuki, Kazuki Tanaka, Chihiro Saito, Shogo Isomura, Satoru Domoto, Junichi Yamaguchi, Hiroshi Niinami, Nobuhisa Hagiwara
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?